Eric J Niesor

Summary

Affiliation: F. Hoffmann-La Roche Ltd

Publications

  1. ncbi Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport
    Eric J Niesor
    Pharmaceuticals Division, F Hoffmann La Roche Ltd, Basel, Switzerland
    J Lipid Res 51:3443-54. 2010
  2. ncbi Lipid and apoprotein composition of HDL in partial or complete CETP deficiency
    Eric J Niesor
    Pharmaceuticals Division, F Hoffmann La Roche Ltd, Metabolic DBA, Grenzacherstrasse 124, Basel, Switzerland
    Curr Vasc Pharmacol 10:422-31. 2012
  3. ncbi Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects
    Eric J Niesor
    Discovery Research Metabolic Disease, F Hoffmann La Roche Ltd, Basel, Switzerland
    Atherosclerosis 219:761-7. 2011
  4. ncbi Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism
    Eric J Niesor
    Pharmaceuticals Division, F Hoffmann La Roche Ltd, Basel, Switzerland
    Curr Opin Lipidol 22:288-95. 2011
  5. ncbi Multidimensional profiling of plasma lipoproteins by size exclusion chromatography followed by reverse-phase protein arrays
    Gregor Dernick
    Discovery Technologies, F Hoffmann La Roche, Ltd, Basel, Switzerland
    J Lipid Res 52:2323-31. 2011
  6. ncbi Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels
    Roger G Clerc
    F Hoffmann La Roche Ltd, Basel, Switzerland
    J Hypertens 28:1676-86. 2010
  7. ncbi MARCO, a macrophage scavenger receptor highly expressed in rodents, mediates dalcetrapib-induced uptake of lipids by rat and mouse macrophages
    Anne Perez
    F Hoffmann La Roche Ltd, Grenzacherstrasse 124, CH 4070 Basel, Switzerland
    Toxicol In Vitro 24:745-50. 2010

Collaborators

Detail Information

Publications7

  1. ncbi Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport
    Eric J Niesor
    Pharmaceuticals Division, F Hoffmann La Roche Ltd, Basel, Switzerland
    J Lipid Res 51:3443-54. 2010
    ..These data suggest that modulation of CETP activity by dalcetrapib does not inhibit CETP-induced pre-β-HDL formation, which may be required to increase reverse cholesterol transport...
  2. ncbi Lipid and apoprotein composition of HDL in partial or complete CETP deficiency
    Eric J Niesor
    Pharmaceuticals Division, F Hoffmann La Roche Ltd, Metabolic DBA, Grenzacherstrasse 124, Basel, Switzerland
    Curr Vasc Pharmacol 10:422-31. 2012
    ..This is only limited by the availability of antibodies against specific apolipoproteins to be investigated...
  3. ncbi Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects
    Eric J Niesor
    Discovery Research Metabolic Disease, F Hoffmann La Roche Ltd, Basel, Switzerland
    Atherosclerosis 219:761-7. 2011
    ..We evaluated the effect of dalcetrapib, a cholesteryl ester transfer protein modulator, on markers of cholesterol homeostasis in healthy subjects...
  4. ncbi Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism
    Eric J Niesor
    Pharmaceuticals Division, F Hoffmann La Roche Ltd, Basel, Switzerland
    Curr Opin Lipidol 22:288-95. 2011
    ....
  5. ncbi Multidimensional profiling of plasma lipoproteins by size exclusion chromatography followed by reverse-phase protein arrays
    Gregor Dernick
    Discovery Technologies, F Hoffmann La Roche, Ltd, Basel, Switzerland
    J Lipid Res 52:2323-31. 2011
    ..This finding was elucidated using this technique...
  6. ncbi Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels
    Roger G Clerc
    F Hoffmann La Roche Ltd, Basel, Switzerland
    J Hypertens 28:1676-86. 2010
    ..The increased mortality observed with the cholesteryl ester transfer protein inhibitor torcetrapib is partly due to increased aldosterone production and blood pressure. The mechanisms underlying these effects were investigated...
  7. ncbi MARCO, a macrophage scavenger receptor highly expressed in rodents, mediates dalcetrapib-induced uptake of lipids by rat and mouse macrophages
    Anne Perez
    F Hoffmann La Roche Ltd, Grenzacherstrasse 124, CH 4070 Basel, Switzerland
    Toxicol In Vitro 24:745-50. 2010
    ..MARCO was expressed at very low levels in human macrophages and was not inducible by LPS. The MARCO receptor may account for the variable species susceptibility towards dalcetrapib-mediated chylomicron uptake by macrophages...